Albomycin δ1

Albomycin δ1 is a selective bacterial ribosome-targeted antibiotic (MIC: 0.0625 μg/mL against S. pneumoniae) . Albomycin δ1 exerts bactericidal activity via covalent binding to 70S ribosomes and irreversible inhibition of peptidyl transferase. Albomycin δ1 is promising for research of S. pneumoniae and S. aureus infections[1][2].

Product Specifications

CAS Number

[12676-11-8]

UNSPSC

12352005

Target

Antibiotic; Bacterial

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Smiles

O[C@H]1[C@H](O)[C@@H](N2C=CC(N(C)C2=O)=O)S[C@@]1([H])[C@H](O)[C@@H](C(O)=O)NC([C@H](CO)NC([C@@H](N3)CCCN(C(C)=O4)O[Fe]546(O7)ON(C(C)=O6)CCC[C@H](NC([C@H](CCCN7C(C)=O5)N)=O)C3=O)=O)=O

Molecular Formula

C36H55FeN10O18S

Molecular Weight

1003.79

References & Citations

[1]Lin Z, et al. Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens. Nat Commun. 2018 Sep 4;9 (1) :3445.|[2]Gadakh B, et al. Synthesis and structural insights into the binding mode of the albomycin δ1 core and its analogues in complex with their target aminoacyl-tRNA synthetase. Bioorg Med Chem. 2020 Sep 1;28 (17) :115645.